fda 503a bulks list bpc-157 category 2 Industry Update: Interim and 503B Lists New Revisions Regulatory Alert: FDA's April 2026
Regulatory Alert: FDA's April 2026 Update on BPC 157 and GHK Cu Holt Law Peptides: Legal and Regulatory Risks 503A Compounding Pharmacies Must Understand Health Law Alliance BREAKING: The FDA just reversed theIR 2023 peptide ban. 12 peptides were just pulled from the Category 2 restricted list: 1. BPC 157 2. Thymosin beta 4 fragment (TB 500) 3. Epitalon 4. GHK Cu (injectable) FDA Adds Several Peptides to Category 2 Bulks List, Restricting Them From Compounding Restore Health Consulting FDA's own advisory committee voted 8 6 Thursday. BPC 157, on the compounding list now, for ulcerative colitis. FDA staff argued against it, laid out the data gaps, the whole case. Panel overruled them
Pay in 4 interest-free payments of $7.16 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 2 - Aug 7


